Health Care·Biotechnology·$6.7B
Arcellx Inc (ACLX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $7 billion, its advancements in cell therapy could significantly impact patient outcomes in the healthcare sector.
EPS (Earnings Per Share)
EPS is a key indicator of a company's profitability, and investors will be keen to see if ACLX can narrow its losses this quarter.
Revenue Growth
Although revenue figures are not available, any indication of growth in this area would signal positive momentum for the company.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
-36.35%
Avg Stock Reaction
+2.14%
In Q4-2025, Arcellx reported an EPS of -$4.07, significantly missing expectations. The stock saw a slight increase of 0.11% the following day, indicating some resilience despite the poor earnings.
Management Promises & Guidance
Overall, expectations for Arcellx are cautious, given the recent history of EPS misses and lack of revenue guidance. Investors are looking for signs of improvement in clinical trial results and cost management.
Bull Case
If Arcellx can demonstrate progress in its clinical trials and reduce its losses, it could lead to a positive re-evaluation of its stock, driving significant gains.
Bear Case
Conversely, if the company continues to miss EPS estimates and fails to provide clarity on revenue generation, it could lead to further declines in stock price.
EPS (Earnings Per Share)
N/AEPS is a key indicator of a company's profitability, and investors will be keen to see if ACLX can narrow its losses this quarter.
Revenue Growth
N/AAlthough revenue figures are not available, any indication of growth in this area would signal positive momentum for the company.
Clinical Trial Progress
N/AUpdates on clinical trials can greatly influence investor sentiment, as successful trials are critical for future revenue potential.
The print will turn on these two things.
Q1
What is the current status of clinical trials for its lead product candidates?
Updates on clinical trials can significantly affect the company's future revenue potential and investor confidence.
Q2
What measures is Arcellx implementing to manage costs effectively?
Effective cost management is crucial for improving financial performance and narrowing losses, which is a key concern for investors.
Why consensus could be wrong
The consensus may underestimate the potential impact of upcoming clinical trial results, which could lead to a more favorable outlook than currently anticipated.
Supporting Evidence
The stock has shown resilience in the past despite poor earnings, suggesting underlying strength.
Recent trends in biotechnology indicate a growing interest in innovative therapies, which could benefit Arcellx.
Management's focus on cost control may yield better-than-expected results.
Key Risk
If clinical trial results show significant promise, it could shift the narrative and lead to a reevaluation of the stock.
Pre-commit to what would confirm each case.
The market is closely watching for signs of operational improvement and clinical progress, which could shift sentiment significantly.
Bull Confirmed If
Demonstrating a significant reduction in EPS losses, ideally below $3.00, would confirm the bull case.
Bear Confirmed If
Continued losses exceeding $4.00 per share would reinforce the bear case.
Implied Move
±N/A
There is currently no options market data available to gauge investor sentiment leading up to the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Arcellx beats EPS expectations and provides positive updates on clinical trials, history suggests a potential average one-day move of +2.88%, confirming a bullish outlook.
In-Line / Cautious
If results are in line with expectations but lack strong guidance, the stock may see muted reactions, reflecting cautious investor sentiment.
Miss
Should the company miss expectations again, history suggests a potential average one-day move of +1.40%, indicating further downside risk.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026